Plasma HAEE in Alzheimer’s disease and healthy controls
Kopylov AT, Kozin SA · 2026 · PNAS Nexus
Reported findings and study design
Cross-sectional LC–MS/MS plasma measurements. Table 1 and Figure 1 report group distributions and ROC analysis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Median plasma HAEE | 143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls. | |
| ROC discrimination | AUC 0.832 (p<0.001), with 84.13% sensitivity and 63.51% specificity at the study cut-off. |
The assay needs independent validation against other causes of cognitive impairment. The authors disclose related patent interests. The study did not administer HAEE.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The assay needs independent validation against other causes of cognitive impairment. The authors disclose related patent interests. The study did not administer HAEE.
Source access
Original full text checked for selected methods and findings.
Source reviewed 2026-11-12.
Source type: Journal publication
Citation and original source
Original source: Kopylov AT, Kozin SA. Plasma HAEE in Alzheimer’s disease and healthy controls PNAS Nexus 2026.
Molekul research summary: https://molekul.io/research/haee-plasma-alzheimers-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry